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doi:10.1016/j.jtcvs.2004.01.023TObjectives: We sought to describe the hemodynamic and clinical outcomes for the
Freestyle aortic root bioprosthesis (Medtronic, Inc, Minneapolis, Minn) in a large
multicenter cohort prospectively followed for 8 years.
Methods: A total of 700 patients (651 [93%]60 years of age) at 8 centers in North
America were followed prospectively after aortic valve replacement with the Free-
style stentless bioprosthesis; the implant technique was subcoronary in 500, total
root in 162, and root inclusion in 38. Follow-up was 3395 patient-years (4.9  2.3
years per patient). Clinical and echocardiographic follow-up was prospectively
obtained at yearly intervals.
Results: For the subcoronary, total root, and root inclusion groups, actuarial freedom
from valve-related death was 96.8% (SE 3.0%), 92.3% (SE 7.7%), and 90.9% (SE
11.2%), respectively, and freedom from structural deterioration was 98.6% (SE
2.0%), 100.0% (SE 0.0%), and 100.0% (SE 0.0%), respectively. Hemodynamics
remained excellent at 6 years. Freedom from moderate or more aortic regurgitation
was 86.0% (SE 5.1%), 98.7% (SE 3.9%), and 97.3% (SE 6.6%), respectively.
Gradients were slightly lower (P  .0009), and the effective orifice area (P  .02)
and freedom from aortic regurgitation were slightly higher (P  .03) with total root
than subcoronary implantation.
Conclusions: The Freestyle stentless aortic root bioprosthesis is a versatile option
for aortic valve replacement. Measures of clinical outcomes and prosthesis dura-
bility remain excellent in multicenter follow-up through 8 years in a population
predominantly older than 60 years at the time of the operation.
The Freestyle aortic root bioprosthesis (Medtronic, Inc, Minneapolis,Minn) is a stentless porcine aortic root prepared by using proprietarylow-pressure and zero-pressure fixation processes and alpha-aminooleic acid leaflet anticalcification treatment, with the aim of optimiz-ing both hemodynamics and bioprosthesis durability. The device canbe implanted as a subcoronary or modified subcoronary valve re-
placement, as a complete aortic root replacement (total root), or as a root inclusion.
Initial implantations in human subjects began in 1992, and the device has been
approved for clinical use in the United States since 1997.
Previously published reports confirm excellent hemodynamics associated with
the Freestyle stentless aortic root.1-5 However, as a bioprosthesis, its usefulness is
affected by its durability. The stentless valve design and tissue anticalcification
treatment might allow for significant mitigation of bioprosthesis calcification and
structural valve failure, which has been supported in animal models6,7 and existing
1,8clinical studies. The purpose of the present report is to describe the hemodynamic
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thesis in a large multicenter cohort prospectively followed
for up to 8 years.
Patients and Methods
Study Population
The multicenter evaluation of the Freestyle stentless aortic root
bioprosthesis began in 1992 at 21 centers in North America and
Europe. In 1997, a long-term study of the valve began at 8 of these
centers, which were selected for patient volume and protocol
adherence. Study sites and clinical investigators are listed in the
Appendix. The study protocol was reviewed and approved by each
participating hospital’s ethics review board; all subjects provided
written informed consent. The long-term study group includes 700
consecutive patients; 651 (93%) of 700 were older than 60 years at
the time of the operation. The implant technique was subcoronary
in 500 (71.4%) patients, total root in 162 (23.1%) patients, and root
inclusion in 38 (5.4%) patients. Most of the subcoronary implants
were of the modified subcoronary variety, with retention of the
noncoronary sinus of Valsalva. Demographic data and patient
characteristics have been previously published.4 The operative
technique has been previously described.1 The distribution of
valve sizes is shown in Table 1. Follow-up was 3395 patient-years
(mean, 4.9  2.3 years per patient; range, 0-9 years).
Clinical and Echocardiographic Data
The collection of clinical and echocardiographic data has been
previously described.1,4 In brief, preoperative clinical data and
surgical data were prospectively recorded for each patient. Patients
were prospectively monitored throughout the postoperative fol-
low-up period for adverse events, following guidelines of the
Society of Thoracic Surgeons and The American Association of
Thoracic Surgeons.9 Both clinical and echocardiographic data
were obtained at specified intervals of within 30 days of discharge,
3 to 6 months after the operation, 1 year after the operation, and
yearly thereafter.
Echocardiograms were obtained at the respective investiga-
tional centers by using clinically standard criteria for analysis. The
mean gradient was calculated by using the modified Bernoulli
equation, correcting for proximal velocity.10 The effective orifice
area (EOA) was calculated by using the continuity equation.10 Left
ventricular (LV) mass index was calculated as previously de-
scribed by means of the modified American Society of Echocar-
diography cube method.4,11 Aortic regurgitation (AR) was graded
as absent, trivial, mild, moderate, or severe on the basis of standard
clinical criteria, including assessment of jet width, circumference,
12
TABLE 1. Valve sizes implanted
Subcoronary Total root Root inclusion
19 mm 31 (6.2%) 8 (4.9%) 0 (0%)
21 mm 103 (20.6%) 22 (13.6%) 4 (10.5%)
23 mm 133 (26.6%) 33 (20.4%) 11 (28.9%)
25 mm 137 (27.4%) 35 (21.6%) 13 (34.2%)
27 mm 96 (19.2%) 64 (39.5%) 10 (26.3%)and eccentricity.
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Continuous data are expressed as means  1 SD. Categoric data
are expressed as percentages. Survival analyses with the Kaplan-
Meier method were used to estimate survival, freedom from valve-
related adverse events, and freedom from AR; the Peto formula
was used to calculate the SE of the estimates. Cox proportional
hazard models were used to test for differences in adverse events
between patients undergoing implantation with the subcoronary
and total root techniques and between patients with indexed EOAs
of less than versus greater than or equal to 0.85 cm2/m2. Repeated-
measures analysis of variance was performed to test for differences
in LV mass index between patient populations. Statistical analysis
was performed with SAS statistical software (SAS Institute, Inc,
Cary, NC).
Results
Clinical Outcomes
Operative death for this population has been previously
described.1,4 Actuarial survival and freedom from valve-
related death through 8 years are shown in Figures 1 and 2.
For patients undergoing implantation with the subcoronary,
total root, and root inclusion techniques, actuarial freedom
from cardiac death at 8 years was 87.8% (SE 5.3%), 88.0%
(SE 9.2%), and 97.1% (SE 6.7%), respectively, and freedom
from noncardiac death was 77.8% (SE 6.3%), 78.3% (SE
11.0%), and 83.3% (SE 13.9%), respectively. There were no
significant differences between implantation techniques in
overall survival (P  .73) or freedom from valve-related
death (P  .63). Freedom from reoperation and freedom
from structural valve deterioration are shown in Figures 3
and 4. There were no significant differences between im-
plant groups in either freedom from reoperation (P .40) or
freedom from structural valve deterioration (P  1.00).
Actual freedom from valve-related death at 8 years was
97.4% (SE 0.8%), 94.6% (SE 3.6%), and 91.5% (SE 4.7%)
for the subcoronary, full root, and root inclusion groups,
respectively. Actual freedom from cardiac death was 89.4%
(SE 1.6%), 88.9% (SE 2.7%), and 97.3 (SE 2.7%); actual
freedom from reoperation was 96.8% (SE 0.9%), 98.7% (SE
0.9%), and 92.1% (SE 4.4%); and actual freedom from
structural valve deterioration was 99.0% (SE 0.6%), 100.0%
(SE 0.0%), and 100.0% (SE 0.0%), respectively.
There were a total of 3 cases of structural valve deteri-
oration, all occurring in the subcoronary group. These oc-
curred in association with right cusp tear in 2 cases, 28
months after implantation of a 21-mm valve in a 77-year-
old woman, and 53 months after implantation of a 25-mm
valve in a 62-year-old woman. The third case occurred in
association with left cusp dehiscence 82 months after im-
plantation of a 25-mm valve in a 62-year-old man. There
was no evidence of calcification in any of the 3 cases.
Hemodynamics
Hemodynamics by valve size early after surgical interven-
1,4tion have been previously reported. Mean gradients,
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are shown in Table 2. Gradients were lower (P .0001) and
EOA was higher (P  .0001) for larger than for smaller
valve sizes. Gradients were lower (P  .0009) and EOA
was higher (P  .02) among patients undergoing implanta-
tion by means of the total root technique than among those
undergoing implantation by means the subcoronary tech-
nique. A decrease in mean gradient and increase in EOA
from early to 1 year after the operation have been previously
described.1,4 In the present analysis there was a small but
Figure 1. Survival through 8 years by implant techniq
techniques in overall survival (P .73). Data labels are
the graph represent patients at risk.
Figure 2. Freedom from valve-related death through
differences between implant techniques in freedom fro
as percentages  SE at 8 years. Numbers below thestatistically significant increase in mean gradient from 1 to
The Journal of Thoracic6 years after the operation among patients with available
data at both 1 and 6 years, which is of doubtful clinical
significance (subcoronary: n 143,   1.3 4.1 mm Hg,
P  .0001; total root: n  37,   0.7  2.2 mm Hg, P 
.05). There was an extremely small but statistically signif-
icant decrease in EOA between 1 and 6 years among sub-
coronary implants (n  139,   0.1  0.4 cm2, P 
.001) but no statistically significant change in EOA among
patients undergoing full root (n 37,   0.1 0.7 cm2,
P  .6) or root inclusion (n  14,   0.1  0.5 cm2,
here were no apparent differences between implant
ented as percentages SE at 8 years. Numbers below
ars by implant technique. There were no apparent
lve-related death (P  .63). Data labels are presented
represent patients at risk.ue. T
pres8 ye
m va
graphP  .5) implantations.
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LV mass index over time is shown in Figure 5. LV mass
index decreased significantly early after aortic valve re-
placement for all implant techniques. Between 1 and 6 years
after the operation, there was a small but statistically sig-
nificant increase in LV mass index. In the first year after the
operation, there was greater decrease in LV mass index
associated with larger than smaller valve sizes (P .01) and
among patients without than with prosthesis-patient mis-
2 2
Figure 4. Freedom from structural valve deterioratio
apparent differences between implant techniques in fr
labels are presented as percentages  SE at 8 years.
Structural valve deterioration.
Figure 3. Freedom from reoperation through 8 years b
between implant techniques in freedom from reoperat
SE at 8 years. Numbers below the graph represent pamatch (indexed EOA, 0.85 cm /m ).
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The prevalence of prosthesis-patient mismatch (defined as
moderate for an indexed EOA of0.85 cm2/m2 or as severe
for an indexed EOA of 0.65 cm2/m2)13 is shown in Table
3. The prevalence of prosthesis-patient mismatch decreased
in the first year after the operation and was lower and
remained lower through 6 years among patients who under-
went total root aortic valve replacement. Analysis of
matched data revealed that prosthesis-patient mismatch (in-
2 2
ough 8 years by implant technique. There were no
m from structural valve deterioration (P  1.00). Data
bers below the graph represent patients at risk. SVD,
plant technique. There were no apparent differences
 .40). Data labels are presented as percentages 
at risk.n thr
eedo
Numy im
ion (P
tientsdexed EOA,0.85 cm /m ) at 1 year resolved by 6 years in
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mismatch developed during the same interval in 25 (19%)
of 129 patients without prosthesis-patient mismatch at 1 year.
The rate of adverse events did not differ significantly for
patients with prosthesis-patient mismatch early after the
operation (indexed EOA  0.85 cm2/m2) compared with
those without patient-prosthesis mismatch. There was a
trend that failed to reach statistical significance toward
lower overall survival (survival at 8 years of 52.6% [SE
4.7%] vs 65.4% [SE 4.2%], P  .10). There were no
differences between groups with or without prosthesis-pa-
tient mismatch in rates of valve-related death (P  .83),
freedom from reoperation (P  1.00), or freedom from
structural valve deterioration (P .23). Evaluation defining
prosthesis-patient mismatch as an indexed EOA of less than
0.65 cm2/m2 also failed to show significant differences in
freedom from adverse events, although a trend was again
evident toward lower survival (8-year survival of 46.7% [SE
12.9%] vs 62.0% [SE 5.8%]).
Aortic Regurgitation
The preponderance of patients in both implant groups had
no or trivial AR through 8 years, and no patient had severe
AR throughout the follow-up period. Freedom from hemo-
dynamically significant AR is shown in Figure 6. Although
the prevalence of AR was extremely low for all implant
techniques, patients having undergone subcoronary implan-
tation were 9.6 times more likely than patients who under-
went total root implantation to have moderate or severe AR
(P  .03).
Discussion
Hemodynamic Outcomes
Stentless valves in general have very good hemodynamic
Figure 5. Left ventricular (LV) mass index through 8 years by
implant technique.characteristics, with low transvalvular gradients and large
The Journal of ThoracicEOAs. The present work confirms that low gradients and
large EOAs associated with the Freestyle stentless aortic
bioprosthesis are maintained at least 6 years after implan-
tation. Mean gradients remain low, and the average indexed
EOA remains at least 1.0 cm2/m2 for all implant types.
Defined as an indexed EOA of less than 0.65 cm2/m2, the
prevalence of prosthesis-patient mismatch was very low
throughout the duration of follow-up. However, defined as
an indexed EOA of less than 0.85 cm2/m2, approximately
one in 4 patients had prosthesis-patient mismatch 6 years
after total root or root inclusion surgery, and approximately
40% had prosthesis-patient mismatch after subcoronary aor-
tic valve replacement. The clinical implications of these
numbers are not clear.
First, there was evidence of excellent LV mass regres-
sion early after surgical intervention, reflecting good relief
of LV outflow obstruction. Although there was a late in-
crease in LV mass index, it was of very small magnitude
and of doubtful clinical relevance. That an increase in LV
mass occurred in the setting of maintained low gradients
and stable EOA suggests that other factors, such as systemic
TABLE 2. Hemodynamics at 1 year and 6 years after the
operation for all valve sizes
Subcoronary Total root Root inclusion
1 Year after the operation
N 410 134 29
MPG (mm Hg) 8.3 5.4 5.4 3.7 5.9 4.0
EOA (cm2) 1.8 0.6 2.0 0.6 2.1 0.9
Indexed EOA
(cm2/m2)
1.0 0.3 1.1 0.3 1.1 0.5
6 Years after the operation
N 138 36 15
MPG (mm Hg) 8.8 6.2 6.0 3.5 6.2 3.8
EOA (cm2) 1.7 0.5 1.9 0.8 2.0 0.7
Indexed EOA
(cm2/m2)
1.0 0.3 1.0 0.4 1.1 0.4
MPG, Mean pressure gradient; EOA, effective orifice area.
TABLE 3. Prosthesis-patient mismatch early and at 1 and 6
years after the operation
Subcoronary Total root Root inclusion
Indexed EOA 0.85 cm2/m2
Early 255/454 (56.2%) 49/148 (33.1%) 20/37 (54.1%)
1 y 136/410 (33.2%) 30/134 (22.4%) 9/29 (31.0%)
6 y 57/138 (41.3%) 10/36 (27.8%) 4/15 (26.7%)
Indexed EOA 0.65 cm2/m2
Early 92/454 (20.3%) 17/148 (11.5%) 8/37 (21.6%)
1 y 49/410 (12.0%) 10/134 (7.5%) 4/29 (13.8%)
6 y 18/138 (13.0%) 2/36 (5.6%) 2/15 (13.3%)
EOA, Effective orifice area.hypertension, might have played a role in its development.
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known to compare favorably with those of stented biopros-
theses.14,15 As such, the prevalence of prosthesis-patient
mismatch that would have occurred in the same population
by using another prosthesis is unknown (but could have
been higher).
Measures of Durability
The present report provides reassuring data that the Free-
style valve remains durable through 8 years after the oper-
ation. Freedom from structural valve failure, freedom from
reoperation, and freedom from hemodynamically significant
AR remained favorable through 8 years for the 3 implant
groups. However, the population studied was predominantly
older than 60 years of age at the time of the operation, and
younger patients would be expected to be at greater risk of
bioprosthesis failure within the observed follow-up period.
Continued assessment will be necessary to define the antic-
ipated durability in the study population.
Differences Between Implant Techniques
Patients were not randomly assigned to implant technique,
and to a large degree, implant technique was influenced by
clinical factors, such as the presence of concomitant aortic
root pathology. Furthermore, relatively few patients under-
went root inclusion aortic valve replacement. As such, the
populations in the different implant groups were dissimilar,
and comparison between groups is problematic. However,
several differences or trends between the groups were evi-
Figure 6. Freedom from moderate or greater aortic re
were at higher risk for aortic regurgitation after mod
presented as percentages  SE at 8 years. Number
regurgitation.dent.
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in freedom from valve-related death, reoperation, or struc-
tural valve deterioration. Freedom from hemodynamically
significant AR was slightly better with the total root tech-
nique compared with that after the subcoronary implant
technique, possibly related to preservation of the intact
porcine root and cusp geometry. Gradients were lower and
EOA was higher among patients undergoing total root com-
pared with subcoronary aortic valve replacement. It is pos-
sible that the absence of surrounding native aorta results in
better hemodynamic performance of the same prosthesis.
However, larger prostheses were used among patients in the
total root replacement group. Whether these observations
are ultimately related to differences in valve sizes implanted
or to hypothetic differences in valve performance, decisions
regarding implant technique likely will be influenced more
by underlying pathology than by small (even if statistically
significant) differences in hemodynamics or AR.
Previously Published Data
Patients included in the present study have been included in
earlier reports with shorter follow-up or in reports based on
single-center experiences. In 1999, Doty and colleagues1
published 5-year data from the multicenter study of the
Freestyle aortic valve. Actuarial freedom from all-cause
death at 5 years was 72.6%  4.8%, 70.8%  4.7%, and
82.9%  4.5% for the subcoronary, total root, and root
inclusion groups, respectively, and overall freedom from
valve-related death was 97.0% at 5 years. At 4 years,
gradients were low, and only 4% of patients had moderate
2 3
tation through 8 years by implant technique. Patients
subcoronary replacement (P  .03). Data labels are
ow the graph represent patients at risk. AR, Aorticgurgi
ified
s belAR. Single-center reports reflecting 5-year and 7-year
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ciates5 reported 8-year follow-up from Wake Forest Uni-
versity, where 100% of implantations were performed as
total root replacements. Survival was 59.8% at 8 years,
gradients were low, and there was a 0% prevalence of
hemodynamically significant AR.
The present report extends the multicenter study of pa-
tients having undergone aortic valve replacement with the
Freestyle stentless bioprosthesis. Overall survival at 8 years
is similar to that reported by Kon and associates5 for pa-
tients undergoing total root replacement. Other measures of
clinical outcomes remain favorable, hemodynamics remain
well preserved, and valve durability remains intact.
Study Limitations
The present study is an observational assessment of out-
comes. Patients were not randomly assigned to various
therapies, and comparison between inherently dissimilar
groups is problematic. Clinical follow-up was available
through 8 years, and continued study will be necessary as
patients reach time points during which valve failure is
more likely. Hemodynamic outcomes were measured
through 6 years because of limited data available thereafter.
Finally, the present study was neither designed nor powered
to test the clinical effect of prosthesis-patient mismatch;
absence of statistically significant differences in outcomes
might be due to sample size.
Conclusions
The Freestyle stentless aortic bioprosthesis has very good
associated hemodynamics that are maintained through 6
years. Measures of clinical outcomes and prosthesis dura-
bility remain excellent in multicenter follow-up through 8
years. There are few differences in clinical outcomes be-
tween implant groups, although hemodynamics and free-
dom from AR appear slightly better after total root replace-
ment. The Freestyle stentless aortic root bioprosthesis is a
versatile option for aortic valve replacement, with durability
that exceeds 8 years in a population predominantly older
than 60 years at the time of the operation.
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Appendix
Study Site Location and Principal Investigator
Hoˆpital Laval Ste-Foy, Quebec, Canada; Paul A. Cartier, MD
Victoria General Hospital, Halifax, Nova Scotia, Canada; David
Ross, MD
Good Samaritan Hospital, Portland, Ore; Albert Krause, MD
Wake Forest University Baptist Medical Center, Winston-Salem,
NC; Neal Kon, MD
Kaiser Permanente Los Angeles Medical Center, Los Angeles,
Calif; Siavosh Khonsari, MD
Lenox Hill Hospital, New York, NY; V. A. Subramanian, MD
Southwest Washington Medical Center, Vancouver, Wash; Albert
Krause, MD
LDS Hospital, Salt Lake City, Utah; Donald B. Doty, MD
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